An Animal Model of Type A Cystinuria Due to Spontaneous Mutation in 129S2/SvPasCrl Mice

Cystinuria is an autosomal recessive disease caused by the mutation of either SLC3A1 gene encoding for rBAT (type A cystinuria) or SLC7A9 gene encoding for b0,+AT (type B cystinuria). Here, we evidenced in a commonly used congenic 129S2/SvPasCrl mouse substrain a dramatically high frequency of kidney stones that were similar to those of patients with cystinuria. Most of 129S2/SvPasCrl exhibited pathognomonic cystine crystals in urine and an aminoaciduria profile similar to that of patients with cystinuria. In addition, we observed a heterogeneous inflammatory infiltrate and cystine tubular casts in the kidney of cystinuric mice. As compared to another classical mouse strain, C57BL/6J mice, 129S2/SvPasCrl mice had an increased mortality associated with bilateral obstructive hydronephrosis. In 129S2/SvPasCrl mice, the heavy subunit rBAT of the tetrameric transporter of dibasic amino acids was absent in proximal tubules and we identified a single pathogenic mutation in a highly conserved region of the Slc3a1 gene. This novel mouse model mimicking human disease would allow us further pathophysiological studies and may be useful to analyse the crystal/tissue interactions in cystinuria.

[1]  M. Méchali,et al.  A spontaneous Cdt1 mutation in 129 mouse strains reveals a regulatory domain restraining replication licensing , 2013, Nature Communications.

[2]  R. Flavell,et al.  NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy , 2013, Kidney international.

[3]  D. Fotiadis,et al.  The SLC3 and SLC7 families of amino acid transporters. , 2013, Molecular aspects of medicine.

[4]  H. Anders,et al.  Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. , 2013, The Journal of clinical investigation.

[5]  M. Daudon,et al.  Characterization and some physicochemical aspects of pathological microcalcifications. , 2012, Chemical reviews.

[6]  D. Goldfarb,et al.  Pathophysiology and treatment of cystinuria , 2010, Nature Reviews Nephrology.

[7]  D. Assimos,et al.  Kidney stones: a global picture of prevalence, incidence, and associated risk factors. , 2010, Reviews in urology.

[8]  A. Evan,et al.  Bladder outlet obstruction in male cystinuria mice , 2010, International Urology and Nephrology.

[9]  M. Daudon,et al.  [Epidemiology of urolithiasis]. , 2011, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[10]  M. Daudon,et al.  [Epidemiology of urolithiasis]. , 2008, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[11]  M. Palacín,et al.  Distinct classes of trafficking rBAT mutants cause the type I cystinuria phenotype. , 2008, Human molecular genetics.

[12]  E. Salido,et al.  Alanine–glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer , 2006, Proceedings of the National Academy of Sciences.

[13]  A. Evan,et al.  Renal function in patients with nephrolithiasis. , 2006, The Journal of urology.

[14]  R. Goldschmeding,et al.  In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Tianxin Yang,et al.  Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. , 2005, American journal of physiology. Renal physiology.

[16]  M. Daudon,et al.  ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  M. Palacín,et al.  Slc7a9-deficient mice develop cystinuria non-I and cystine urolithiasis. , 2003, Human molecular genetics.

[18]  M. Nehls,et al.  A mouse model for cystinuria type I. , 2003, Human molecular genetics.

[19]  Li-jun Ma,et al.  Model of robust induction of glomerulosclerosis in mice: importance of genetic background. , 2003, Kidney international.

[20]  M. Daudon,et al.  Cystine crystal volume determination: a useful tool in the management of cystinuric patients , 2003, Urological Research.

[21]  M. Gallucci,et al.  Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. , 2002, Journal of the American Society of Nephrology : JASN.

[22]  F. Verrey,et al.  Apical heterodimeric cystine and cationic amino acid transporter expressed in MDCK cells. , 2002, American journal of physiology. Renal physiology.

[23]  P. Rieu,et al.  Medical treatment of cystinuria: critical reappraisal of long-term results. , 2000, The Journal of urology.

[24]  Muriel T. Davisson,et al.  Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice , 1997, Nature Genetics.